Immunogenicity of a single dose mRNA vaccine in SARS-CoV-2 exposed subjects: A systematic review
Keywords:Immunity, SARS-CoV-2, Vaccination, COVID-19, mRNA
Background: The novel coronavirus is quickly spreading and mutating, putting the public health and lifestyle in shambles. The development and approval of mRNA vaccines came up as a breakthrough. The breadth of immune response after a single-dose vaccination in the already infected population is discovered for understanding the hybrid immunity and side effects associated with second dose. Administering a single-dose vaccine to the seropositive population can spare the doses for the population at higher risk.
Methods: PubMed, Web of Science, Google scholar, medRxiv and Cochrane library were explored to extract the original data on the efficacy of single-dose mRNA vaccines in seropositive subjects. The Cochrane risk of bias tool was used to assess the risk of bias in the studies.
Results: 6 studies evaluating the immunogenicity of single-dose mRNA vaccine were incorporated along with some observational studies and literature. These studies present promising evidence for administering only single-dose mRNA vaccine in seropositive subjects, providing biphasic immune response of higher breadth and duration.
Limitations: Most studies had a small sample size, did not correlate the results with higher age groups, with potential risk factors and the percentage of individuals who contracted breakthrough infections.
Conclusions: Single-dose mRNA vaccine can be immunogenic and protective enough for already seropositive population by increasing the number of Spike protein-specific memory B-cells. Vaccination schedules based on existing anti-body titers in such individuals can spare doses for vulnerable groups, especially when there is limited production and supply of vaccines worldwide.
How to Cite
Copyright (c) 2022 Jagtar Singh, Seema Thakur
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The authors agreed following terms while submitting the article:
- I and coauthors retain copyright and grant the journal right of first publication with the work and also agree that, if accepted by the editorial team, shall be licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (Articles can be shared and adapted, provided the attribution for the work is given and that the work is not used for commercial purposes), full details of which can be found here.
- I, on behalf of myself and my co-authors, authorize that:
- the article is original and was not published in any other peer-reviewed journal, and is not under consideration by any other journal, and does not violate any existing copyright or any other third party rights.